HemaSphere (Jun 2022)
P841: EXTRACELLULAR VESICLE PROTEINS AS BIOMARKER OF OUTCOME IN MULTIPLE MYELOMA - A REAL-WORLD STUDY
- E. Arnault Carneiro,
- B. Ferreira,
- C. Pestana,
- F. Barahona,
- J. Caetano,
- R. Lopes,
- P. Lúcio,
- M. Neves,
- H. C. Beck,
- A. S. Carvalho,
- R. Matthiesen,
- B. Costa-Silva,
- C. João
Affiliations
- E. Arnault Carneiro
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- B. Ferreira
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- C. Pestana
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- F. Barahona
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- J. Caetano
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- R. Lopes
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- P. Lúcio
- 5 Hemato-Oncology Unit, Champalimaud Foundation
- M. Neves
- 5 Hemato-Oncology Unit, Champalimaud Foundation
- H. C. Beck
- 7 Centre for Clinical Proteomics, Odense University Hospital, Odense, Denmark
- A. S. Carvalho
- 8 Computational and Experimental Biology, CEDOC, NOVA Medical School
- R. Matthiesen
- 8 Computational and Experimental Biology, CEDOC, NOVA Medical School
- B. Costa-Silva
- 9 Systems Oncology Group, Champalimaud Foundation, Lisbon, Portugal
- C. João
- 1 Myeloma Lymphoma Research Group, Champalimaud Foundation, Lisbon
- DOI
- https://doi.org/10.1097/01.HS9.0000846248.41413.61
- Journal volume & issue
-
Vol. 6
pp. 735 – 736
Abstract
No abstracts available.